# Monitoring of the Lenalidomide Pregnancy Prevention Programme (PPP) Implementation and Effectiveness in Germany (Lena-PIE Germany)

First published: 14/02/2022

**Last updated:** 02/07/2024





# Administrative details

EU PAS number	
EUPAS45747	
Study ID	
45853	
DARWIN EU® study	
No	
Study countries  Germany	

#### Study description

Evaluation of the outcome indicator (safety outcome): (i) Immediate follow-up and root-cause analysis of all pregnancy cases in association with an exposition to Lenalidomid AL Hartkapseln or Lenalidomid STADA Hartkapseln in Germany reported to STADA. (ii) Systematic database review in STADA's safety database to ensure that no pregnancy case in association with an exposition to Lenalidomid AL Hartkapseln or Lenalidomid STADA Hartkapseln in Germany was missed. Follow-up and root-cause analysis of missed cases. (iii) Systematic review of EudraVigilance data to identify pregnancy cases in association with an exposition to Lenalidomid AL Hartkapseln or Lenalidomid STADA Hartkapseln in Germany not known to STADA. Data entry and processing in STADA's safety database, follow-up and root-cause analysis of cases not known.

#### **Study status**

Ongoing

#### Research institutions and networks

#### **Institutions**

### STADA Arzneimittel

First published: 01/02/2024

Last updated: 01/02/2024



#### Contact details

#### **Study institution contact**

Sonja Gomez Perez Sonja.Gomez-Perez@stada.de

Study contact

Sonja.Gomez-Perez@stada.de

#### **Primary lead investigator**

Markus Torben Schweimer

**Primary lead investigator** 

# Study timelines

#### Date when funding contract was signed

Planned: 06/01/2022

Actual: 06/01/2022

#### Study start date

Planned: 18/02/2022

Actual: 18/02/2022

#### Data analysis start date

Planned: 18/02/2027

#### **Date of final study report**

Planned: 18/02/2028

# Sources of funding

• Pharmaceutical company and other private sector

# More details on funding

STADA Arzneimittel AG

# Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

# Other study registration identification numbers and links

STADA study code: PASS-37480-21-0245

# Methodological aspects

Study type

Study type list

Study type:

Not applicable

#### Main study objective:

The objectives of this study are to identify and follow-up on all pregnancies which occur in association with an exposition to Lenalidomid AL Hartkapseln or Lenalidomid STADA Hartkapseln in Germany, to perform a root-cause analysis for such identified cases, and to identify causes that could indicate a failure or weakness of the PPP.

# Study drug and medical condition

#### Name of medicine, other

Lenalidomid AL 2,5 / 5 / 7,5 / 10 / 15 / 20 / 25 mg Hartkapseln, Lenalidomid STADA 2,5 / 5 / 7,5 / 10 / 15 / 20 / 25 mg Hartkapseln

#### Medical condition to be studied

Exposure during pregnancy

# Population studied

#### Age groups

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

#### **Special population of interest**

Pregnant women

# Study design details

#### **Outcomes**

(i) Pregnancy in female patient: conception up to 4 weeks after lenalidomide exposition in female patient, (ii) Pregnancy in female partner of male patient: conception up to 7 days after lenalidomide exposition in male patient.

#### Data analysis plan

Data analysis will be performed as follows: (i) Single case analysis of all pregnancy cases in association with an exposition to Lenalidomid AL Hartkapseln or Lenalidomid STADA Hartkapseln in Germany reported to or identified by STADA, (ii) Descriptive statistics for summarizing data from pregnancy cases in association with an exposition to Lenalidomid AL Hartkapseln or Lenalidomid STADA Hartkapseln.

## Data management

#### Data sources

#### **Data sources (types)**

Other

Spontaneous reports of suspected adverse drug reactions

#### Data sources (types), other

Systematic database review

# Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

#### **Check logical consistency**

Unknown

# Data characterisation

#### **Data characterisation conducted**

No